SIRT 2‐dependent IDH 1 Deacetylation Inhibits Colorectal Cancer and Liver Metastases
Bo Wang,Yingjiang Ye,Xin Yang,Boya Liu,Zhe Wang,Shuaiyi Chen,Kewei Jiang,Wei Zhang,Hongpeng Jiang,Harri Mustonen,Pauli Puolakkainen,Shan Wang,Jianyuan Luo,Zhanlong Shen
DOI: https://doi.org/10.15252/embr.201948183
IF: 9.071
2020-01-01
EMBO Reports
Abstract:Article5 March 2020free access Transparent process SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases Bo Wang Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Yingjiang Ye Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Xin Yang Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Boya Liu Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Zhe Wang Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Shuaiyi Chen Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Kewei Jiang Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Wei Zhang orcid.org/0000-0002-2001-1052 Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Hongpeng Jiang Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Harri Mustonen Department of Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland Search for more papers by this author Pauli Puolakkainen Department of Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland Search for more papers by this author Shan Wang Corresponding Author [email protected] orcid.org/0000-0003-3396-5936 Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Jianyuan Luo Corresponding Author [email protected] orcid.org/0000-0001-6057-2914 Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Zhanlong Shen Corresponding Author [email protected] orcid.org/0000-0002-8717-2686 Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Bo Wang Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Yingjiang Ye Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Xin Yang Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Boya Liu Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Zhe Wang Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Shuaiyi Chen Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Kewei Jiang Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Wei Zhang orcid.org/0000-0002-2001-1052 Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Hongpeng Jiang Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Harri Mustonen Department of Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland Search for more papers by this author Pauli Puolakkainen Department of Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland Search for more papers by this author Shan Wang Corresponding Author [email protected] orcid.org/0000-0003-3396-5936 Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Jianyuan Luo Corresponding Author [email protected] orcid.org/0000-0001-6057-2914 Department of Medical Genetics, Peking University Health Science Center, Beijing, China Search for more papers by this author Zhanlong Shen Corresponding Author [email protected] orcid.org/0000-0002-8717-2686 Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China Search for more papers by this author Author Information Bo Wang1,‡, Yingjiang Ye1,‡, Xin Yang2, Boya Liu2, Zhe Wang2, Shuaiyi Chen2, Kewei Jiang1, Wei Zhang1, Hongpeng Jiang1, Harri Mustonen3, Pauli Puolakkainen3, Shan Wang *,1, Jianyuan Luo *,2 and Zhanlong Shen *,1 1Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing, China 2Department of Medical Genetics, Peking University Health Science Center, Beijing, China 3Department of Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland ‡These authors contributed equally to this work *Corresponding author. Tel: +86 1088324479; Fax: +86 1088324479; E-mail: [email protected] *Corresponding author. Tel: +86 82805861; Fax: +86 62015582; E-mail: [email protected] *Corresponding author. Tel: +86 1088324479; Fax: +86 1088324479; E-mail: [email protected] EMBO Rep (2020)21:e48183https://doi.org/10.15252/embr.201948183 PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Abstract Protein lysine acetylation affects colorectal cancer (CRC) distant metastasis through multiple pathways. In a previous proteomics screen, we found that isocitrate dehydrogenase 1 (IDH1) is hyperacetylated in CRC primary tumors and liver metastases. Here, we further investigate the function of IDH1 hyperacetylation at lysine 224 in CRC progression. We find that IDH1 K224 deacetylation promotes its enzymatic activity and the production of α-KG, and we identify sirtuin-2 (SIRT2) as a major deacetylase for IDH1. SIRT2 overexpression significantly inhibits CRC cell proliferation, migration, and invasion. IDH1 acetylation is modulated in response to intracellular metabolite concentration and regulates cellular redox hemostasis. Moreover, IDH1 acetylation reversely regulates HIF1α-dependent SRC transcription which in turn controls CRC progression. Physiologically, our data indicate that IDH1 deacetylation represses CRC cell invasion and migration in vitro and in vivo, while the hyperacetylation of IDH1 on K224 is significantly correlated to distant metastasis and poor survival of colorectal cancer patients. In summary, our study uncovers a novel mechanism through which SIRT2-dependent IDH1 deacetylation regulates cellular metabolism and inhibits liver metastasis of colorectal cancer. Synopsis SIRT2 inhibits colorectal cancer cell invasion and metastasis by regulating IDH1 acetylation on K224. SIRT2 deacetylates IDH1 on Lys224 in colorectal cancer. IDH1 K224 acetylation activates HIF1α/SRC axis to promote colorectal cancer metastasis. IDH1 acetylation predicts poor prognosis in colorectal cancer. Introduction Colorectal cancer (CRC) is one of the most common malignancies and one of the major causes of morbidity and mortality worldwide. Approximately 50% of patients with CRC develop liver metastases during their course of disease 1. Despite remarkable progress in cancer therapy, the prognosis for CRC patients with distant metastases remains unsatisfactory 2, 3. In addition, the molecular mechanisms underlying the progression and liver metastasis of CRC still remain unclear. Protein post-translational modification (PTM), especially lysine acetylation, has been reported to be essential in cancer progression. Protein acetylation regulates cancer proliferation through controlling multiple cellular pathways, such as cell cycle, apoptosis, and different metabolism pathways. Metabolism reprogramming is a hallmark for tumors maintaining proliferation rates accompanying the malignant phenotype. The acetylation of key oncogenic enzymes affects the enzymatic and non-enzymatic activity and subsequently promotes tumor progression. IDH1 is a NADP+-dependent enzyme located in the cytoplasm that converts isocitrate to α-ketoglutarate (α-KG). Its mutant form converts α-KG to the oncometabolite 2-hydroxyglutarate (2-HG) and induces epigenetic and cell signaling alterations, thus causing tumorigenesis 4, 5. Compared to primary gliomas, isocitrate IDH1 mutations have been detected in more than 70% of secondary gliomas; among those, arginine 132 has been found in nearly all cases 6, 7. IDH1 has recently received great attention because of its involvement in glutamine metabolism in cancer cells. Despite that rare IDH1 mutations are found in colon cancer samples, the glutamine addiction of colon cancer cells suggests that IDH1 may also have an important role in CRC progression. Nevertheless, IDH1 acetylation modification and its function in tumorigenesis have not yet been reported. Sirtuin-2 (SIRT2) is a cytoplasmic NAD-dependent protein deacetylase, which can serve as a histone deacetylase with a preference for histone H4 lysine 16 (H4K16Ac), and can affect chromosomal condensation during cell mitosis 8, 9. SIRT2 deacetylates several notable metabolic enzymes or transcription factors, including glucose-6-phosphate 1-dehydrogenase (G6PD), phosphoglycerate mutase (PGAM), ATP-citrate synthase (ACLY), forkhead box protein O3 (FOXO3), and peroxiredoxin-1 (Prdx-1) 10-14, which affects cell function. In addition, preclinical studies have shown that SIRT2 deficit mice may develop mammary tumors, hepatocellular carcinomas, and gastrointestinal tumors 15, 16, which suggests that SIRT2 could be a target for cancer therapeutic strategy. Yet, other studies have reported on oncogenic characteristic of SIRT2 in leukemia and breast cancer 17, 18. Therefore, the precise role of SIRT2 acting as oncogene or tumor suppressor remains elusive and is probably regulated by its downstream targets. In our previous study, we used mass spectrometry-based quantitative proteomics to quantify dynamic changes of non-histone protein acetylation between matched primary colorectal cancer and liver metastatic tumor specimens. We found aberrant acetylation levels in several cellular metabolism enzymes during colorectal cancer progression and liver metastasis 19. In the present study, we further investigated the function of IDH1 hyperacetylation at lysine 224 in colorectal cancer progression and liver metastases. We discovered that SIRT2 could deacetylate IDH1 at K224 and exhibit tumor suppression function in colon cancer cell model through IDH1 enzymatic activities and HIF1α-SRC transcription axis. Deacetylation of IDH1 K224 by SIRT2 significantly inhibited the malignant behaviors of CRC cells in vitro and in vivo and predicted poor survival in colorectal cancer samples. These findings further elucidate SIRT2-dependent IDH1 acetylation treatment of liver metastasis in CRC. Results Identification of functional acetylation sites in IDH1 In our previous study 19, we found eight proteins with eight acetylated sites which showed more than 2.5-fold changes at acetylation levels, indicating the potential function of these acetylated proteins in colorectal cancer progression and liver metastases (Table 1). In this study, we further evaluated the acetylation levels of these proteins in CRC cell lines. Briefly, we found decreased acetylation levels of K224R on IDH1 or K112R on CSRP1 (Fig EV1A). Furthermore, after performing a cell invasion assay, we found that the overexpression of IDH1 K224R was able to inhibit cell invasive behavior, while no effect was observed for CSRP1 K112R (Fig EV1B). Hence, IDH1 K224 acetylation was selected for further investigation. Table 1. Differentially expressed acetylation sites obtained in 3 paired samples according to acetylation |Diff| of metastases vs. tumor ≥ 2.5 ProtDesc Position Meta/Tumor Acetylation |Diff| Total protein |Diff| TPM2 152 Down 4.031 1.188 ADH1B 331 Up 3.807 1.077 GLUD1 84 Up 3.711 1.098 ASS1 58 Up 3.067 1.153 CSRP1 112 Down 2.973 1.126 TAGLN 21 Down 2.946 1.219 IDH1 224 Up 2.911 1.055 VTN 275 Up 2.603 1.162 ProtDesc: protein name; Position: acetylation site; Meta/Tumor: liver metastases/colorectal primary tumor; |Diff|: absolute value of the differences. Click here to expand this figure. Figure EV1. IDH1 K224 is confirmed as the object for further investigation A. Acetylation levels of protein candidates were assessed by Western Blot. K224R on IDH1 or K112R on CSRP1 showed decreased acetylation levels comparing to others (Acetylation level of ADH1B or VTN was failed to be detected, data not shown). B. Transwell assay showed IDH1 K224R could inhibit cell invasion but CSRP1 K112R had no such effect. Results were expressed as mean ± SD of three independent experiments (n ≥ 3 per experimental condition). Differences between groups were evaluated with a two-tailed unpaired Student's t-test. **P < 0.01. C. IDH1 K224 is evolutionarily conserved from C. elegans to humans. The sequences of IDH1 were aligned of five species. Acetylation lysine 224 identified by proteomic study was highlighted in red. D. IDH1 protein levels after knockout or treated with empty vector, wild-type, K224R and K224Q. Download figure Download PowerPoint To confirm IDH1 acetylation, we treated HEK293T cells with trichostatin A (TSA) and nicotinamide (NAM), the inhibitors of HDAC class I and II or sirtuins, respectively. The immunoprecipitated acetylated IDH1 was increased under treatment of NAM, suggesting that IDH1 acetylation was controlled by sirtuins (Fig 1A). We mutated all the candidate acetylated lysine sites of IDH1 (from UniProt database) to arginine (R) which mimicked the deacetylated states of protein. As shown in Fig 1B, only K224R showed significant lower acetylation levels, indicating that K224 is the major site for IDH1 acetylation. Figure 1. SIRT2 deacetylates IDH1 on K224 A. IDH1 acetylation levels upon treatment with NAM or TSA. Flag-tagged IDH1 was ectopically expressed in HEK293T cells treated with NAM (5 mM) and/or TSA (0.5 mM) for the indicated time period. B. Five putative lysine residues were mutated. Acetylation levels of Flag-bead-purified IDH1 were determined by Western blot analysis using a pan-anti-acetyl lysine antibody. Relative IDH1 acetylation ratios were calculated after normalizing against Flag. C. Mutation of IDH1 K224R and K224Q resulted in altered acetylation levels using Western blot. D. IDH1 catalytic activity of IDH1 K224 mutants in vitro. Wild-type IDH1 and K224R, K224Q mutants were expressed in HEK293 cells. Proteins were purified by immunoprecipitation (IP), IDH1 levels were normalized for protein, and activity assays were performed. E, F. Steady-state kinetic analysis of IDH1 and variants in HEK293T cells. Comparison of IDH1 WT and K224R and K224Q showed that the K224 site was important in catalysis. G. IDH1 directly interacted with SIRT2 but not SIRT1. SIRT2 deacetylated IDH1 effectively. Flag-tagged IDH1 and HA-tagged SIRT1 or SIRT2 were co-transfected into cells. The acetylation level of Flag-bead-purified IDH1 and the protein association between IDH1 and SIRT1 or SIRT2 were determined by Western blot. H. Co-immunoprecipitation showed endogenous proteins of IDH1 and SIRT2 interacted with each other. I. SIRT2 interacted with IDH1 in vitro. GST pull-down assay with GST-fused SIRT2 and Flag-tagged IDH1 proteins. J. Acetylation level of endogenous IDH1 K224 when treated with SIRT1 or SIRT2 by Western blot analysis. K. IDH1 K224 deacetylation was dependent on SIRT2 catalytic activity. SIRT2 H187Y was a catalytically inactive mutant. Data information: All results were expressed as mean ± SD of three independent experiments (n ≥ 3 per experimental condition). For multiple comparisons in (D), a one-way ANOVA with Newman–Keuls post hoc test was used to test for statistical significance. For (E, F), statistical significance was determined using the two-way ANOVA followed by Tukey's post hoc test. *P < 0.05 and **P < 0.01. Download figure Download PowerPoint Then, we determined the in vitro enzymatic activities of IDH1 mutants, K224R and K224Q, expressed in HEK293T cells and found that IDH1 K224Q mutants had a greater than 40% reduction in activity as compared with the wild-type (WT) IDH1 whereas IDH1 K224R mutants had an enhancement (Fig 1C and D). To investigate the mechanism by which K224 acetylation might affect IDH1 activity, we recombinantly expressed and purified human wild-type IDH1 and the K224R and K224Q mutants from E. coli. Steady-state kinetic analysis of IDH1 and variants indicated that substitution of K224 with arginine (R) or glutamine (Q) could alter the Km values for isocitrate and NADP+ and exhibited a change in Vmax when compared with WT (Fig 1E and F, Table 2). Table 2. Steady-state kinetic analysis of IDH1 WT and mutants NADP+ Isocitrate WT Km(μM) 4.7 ± 0.9 5.2 ± 0.6 Vmax (μmol/min/mg) 41.1 ± 2.4 56.5 ± 2.0 K224R Km(μM) 3.9 ± 0.7 3.9 ± 0.5 Vmax(μmol/min/mg) 44.0 ± 2.2 63.3 ± 2.1 K224Q Km(μM) 8.6 ± 1.1 7.5 ± 1.0 Vmax(μmol/min/mg) 16.0 ± 1.5 16.4 ± 1.6 SIRT2 deacetylates IDH1 on K224 SIRT1, SIRT2, SIRT6, and SIRT7 in sirtuins family might regulate cytoplasmic protein acetylation. As IDH1 is located in cytoplasm, we explored the relationship between IDH1 acetylation and sirtuins mentioned above. After co-transfection of Flag-IDH1 and HA-SIRT1 or HA-SIRT2 or HA-SIRT6 or HA-SIRT7 in HEK293T cells, we found that IDH1 directly interacted with SIRT2, but not with SIRT1 (Fig 1G), SIRT6 and SIRT7 (Fig EV2B); in addition, IDH1 acetylation levels were downregulated by SIRT2 as well. Consistently, endogenous IDH1 interacted with SIRT2 in HCT116 cells other than SIRT1 (Fig 1H). We also performed the GST pull-down assay and confirmed that SIRT2 can interact with IDH1 in vitro (Fig 1I). Click here to expand this figure. Figure EV2. IDH1 deacetylation is specifically regulated by SIRT2 A. CRC cells were treated with five different KATs. IDH1 K224 was acetylated by CBP or P300. B. IDH1 interacts with SIRT2, but not SIRT6 and SIRT7. Flag-tagged IDH1 was ectopically expressed in HEK293T cells together with the individual HA-tagged SIRT as indicated. C. Knockdown of SIRT2 resulted in upregulation of IDH1 K224 acetylation level. D. K224 acetylation-specific antibody was generated through rabbit immunization. No. 1 or 2 refers to the acetyl-K224 peptide while No. 3 stands for the unmodified one as negative control. E. The purified antibody reacted strongly with the 47 KD IDH1 protein on extract from mouse liver tissue and HeLa cells. F. Transwell assay evaluating the invasion abilities of HCT116 cells after transfection of SIRT2 or with IDH1 K224Q. G. Cell migration ability was evaluated by wound healing assay in HCT116 cells. H. Colony formation ability after overexpression of SIRT2 or with IDH1 K224Q. Data information: All results were expressed as mean ± SD of three independent experiments (n ≥ 3 per experimental condition). For (F, G, and H), differences between groups were evaluated with a two-tailed unpaired Student's t-test. *P < 0.05 and **P < 0.01. Download figure Download PowerPoint To further investigate the role of K224 acetylation on IDH1, we constructed a K224-specific antibody (Figs EV2D and EV3A). As expected, SIRT2, but not SIRT1, greatly decreased the acetylation levels on K224 site (Fig 1J). HEK293T cells were co-transfected with IDH1 and wild-type (WT) SIRT2 or enzymatically defective mutant SIRT2 H187Y; compared with SIRT2 WT, SIRT2 H187Y lost IDH1 K224 deacetylation ability (Fig 1K). Taken together, IDH1 K224 acetylation may have an important role in colorectal cancer progression and liver metastases and SIRT2 is the major deacetylase responsible for the regulation of IDH1 K224 acetylation. Click here to expand this figure. Figure EV3. IDH1 K224Ac, HIF1α, or SRC protein levels are detected by immunohistochemistry methods in clinical samples A. Acetyl-IDH1 K224 antibody was used in clinical samples. After treatment with corresponding peptides, the signal of IDH1 K224Ac was significantly diminished, indicating that IDH1 K224 peptides successfully blocked the acetylation antibody. B. HIF1α or SRC protein expression in CRC and the adjacent normal tissues. Download figure Download PowerPoint SIRT2 is a tumor suppressor in CRC To investigate the function of SIRT2 in CRC tumorigenesis, we performed a number of cellular tumor biological assays. We found that the overexpression of SIRT2 could dramatically decrease CRC cell proliferation, migration, and cell invasive behavior (Fig 2A–C). Moreover, overexpression of SIRT2 induced cell cycle S phase arrest phenotype (Fig 2D). However, after treated with AGK2 (exclusive SIRT2 inhibitor) or SIRT2 siRNA in HCT116 cells, significantly increased cell invasion, migration, and colony formation were detected. All these experiments demonstrated that SIRT2 inhibits colorectal cancer cell proliferation and invasion. Figure 2. SIRT2 is a tumor suppressor in CRC A. Colony formation ability after transfection of SIRT2 plasmids, AGK2, and SIRT2 siRNA. B. Transwell assay was performed to evaluate the invasion abilities of HCT116 cells after overexpression or downregulation of SIRT2 or treated with AGK2. Stained cells in the lower chambers were quantified. C. Cell migration ability was assessed by wound healing assay in HCT116 cells. D. Cell cycle distribution was evaluated flow cytometrically after treatment with SIRT2 plasmids, SIRT2 siRNA, or AGK2. E. Immunohistochemical analysis of SIRT2 protein in representative colorectal tissue specimens is shown (magnification ×100). Weak cytoplasmic staining for SIRT2 was observed in CRC tissues and metastatic tissues, whereas strong cytoplasmic staining was observed in non-cancerous tissues. Data information: All results were expressed as mean ± SD of three independent experiments (n ≥ 3 per experimental condition). For (A, B, and D), statistical significance was assessed with the one-way ANOVA with Newman–Keuls post hoc test. For (C), statistical significance was assessed with the two-way ANOVA followed by Tukey's post hoc test. *P < 0.05 and **P < 0.01. Download figure Download PowerPoint Next, SIRT2 antibodies were used to detect the expression levels of SIRT2 in CRC primary tissues and their corresponding adjacent normal tissues, as well as liver metastatic tumors. As shown in Fig 2E, SIRT2 expression was significantly decreased in CRC tissues or liver metastases than in corresponding colorectal normal tissues. These data suggest that the downregulation of SIRT2 could lead to CRC progression and liver metastases. IDH1 acetylation senses metabolite concentration and regulate cellular redox hemostasis The benefit of IDH1 for rapidly growing tumorigenic cells is believed to result from a decreased IDH1 activity. To further define the physiologic functions of the SIRT2-IDH1 regulation, we first examined the effect of IDH1 K224 acetylation and enzymatic activities under different metabolite concentrations. Given that glucose is the major carbon and energy source for cancer cell proliferation, we treated HCT116 cells with high glucose levels. High glucose concentration resulted in increased K224 acetylation levels of IDH1 with reduced IDH1 activity in a dose-dependent manner (Figs 3A and B, and EV4A and B). Recent studies have underlined that cancer cells survive for their glutamine addiction 20, 21. Consistent with these data, IDH1 K224 acetylation was increased with high glutamine in a dose-dependent manner with decreased IDH1 activity (Figs 3C and D, and EV4C). Thus, IDH1 acetylation sensed the metabolite concentration and tightly controlled IDH1 enzymatic activities. We further investigated the function of SIRT2 in this regulation process. Knockdown of SIRT2 in HCT116 cells abrogated the effect of changing the K224 acetylation levels under high glucose or glutamine treatment (Fig 3E and F), suggesting the pivotal regulating role of SIRT2 in IDH1 enzymatic activities. Figure 3. IDH1 acetylation senses metabolite concentration and regulate cellular redox hemostasis A, B. IDH1 K224 acetylation level was enhanced with increasing glucose concentration. Flag-IDH1 was overexpressed in cells treated with increased concentrations of glucose for 6 h. IDH1 proteins were purified by Flag beads, and then, IDH1 K224 acetylation level was determined by Western blot and IDH1 catalytic activity was assessed. C, D. IDH1 K224 acetylation level was upregulated, and IDH1 activity was weakened with increasing glutamine concentration. Flag-IDH1 was overexpressed in cells treated with increased glutamine for 6 h. IDH1 proteins were purified by Flag beads, and the K224 acetylation level of IDH1 was determined by Western blot analysis, and then, IDH1 catalytic activity was evaluated. E, F. Downregulation of SIRT2 diminished the effect of glucose or glutamine on changing IDH1 K224 acetylation. Flag-tagged IDH1 was overexpressed in HCT116 cells with or without transient SIRT2 knockdown. The cells were treated with different concentrations of glucose (E) and glutamine (F). G. IDH1 K224 deacetylation regulated cellular NADPH/NADP+ redox in cells. In HCT116 stable cells with IDH1 knockout and re-expressing the indicated proteins, the ratio of NADPH/NADP+ in cells was measured as followed by manufacturer's instruction. H. IDH1 K224 deacetylation promoted GSH production in HCT116 cells. In HCT116 stable cells with IDH1 knockout and re-expressing the indicated proteins, the ratio of GSH/GSSG was assessed as followed by manufacturer's instruction. I. IDH1 K224 deacetylation suppressed cellular ROS levels in HCT116 cells. ROS was determined in cells under non-stressed condition or exposed to menadione. *P < 0.05 and **P < 0.01. Data information: All results were expressed as mean ± SD of three independent experiments (n ≥ 3 per experimental condition). For (B, D, G, and H), statistical significance was assessed with the one-way ANOVA with Newman–Keuls post hoc test. For (I), statistical significance was assessed with the two-way ANOVA followed by Tukey's post hoc test. *P < 0.05 and **P < 0.01. n.s. = not significant. Download figure Download PowerPoint Click here to expand this figure. Figure EV4. IDH1 acetylation level regulates α-KG and metabolite concentration A. Cellular α-KG levels decreased with increasing IDH1 K224Q expression. The α-KG level in cells transfected with empty vector was set as 100%. B, C. The endogenous IDH1 K224 acetylation level was enhanced with increasing glucose or glutamine. D. Knocking out of IDH1 inhibited NADPH production in HCT116 cells. E. Knocking out of IDH1 repressed GSH production in HCT116 cells. **P < 0.01. Data information: All results were expressed as mean ± SD of three independent experiments (n ≥ 3 per experimental condition). For (A), statistical significance was assessed with a one-way ANOVA with Newman–Keuls post hoc test. For (D and E), differences between groups were evaluated with a two-tailed unpaired Student's t-test. **P < 0.01. Download figure Download PowerPoint IDH1 and its enzymatic reaction product α-KG are indispensable for transition between NADP+ and NADPH, whose ratio displays cellular redox balance 22. To investigate the role of IDH1 K224 acetylation in this process, we knocked down IDH1 in HCT116 cells by CRISPR/Cas9 and generated fo
What problem does this paper attempt to address?
-
SIRT2‐dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases
P. Puolakkainen,Xin Yang,Bo Wang,Hongpeng Jiang,Wei Zhang,Zhanlong Shen,Shuaiyi Chen,Zhe Wang,Shan Wang,H. Mustonen,Jianyuan Luo,Y. Ye,Boya Liu,K. Jiang
DOI: https://doi.org/10.15252/embr.201948183
IF: 9.071
2020-03-05
EMBO Reports
Abstract:Protein lysine acetylation affects colorectal cancer (CRC) distant metastasis through multiple pathways. In a previous proteomics screen, we found that isocitrate dehydrogenase 1 (IDH1) is hyperacetylated in CRC primary tumors and liver metastases. Here, we further investigate the function of IDH1 hyperacetylation at lysine 224 in CRC progression. We find that IDH1 K224 deacetylation promotes its enzymatic activity and the production of α‐KG, and we identify sirtuin‐2 (SIRT2) as a major deacetylase for IDH1. SIRT2 overexpression significantly inhibits CRC cell proliferation, migration, and invasion. IDH1 acetylation is modulated in response to intracellular metabolite concentration and regulates cellular redox hemostasis. Moreover, IDH1 acetylation reversely regulates HIF1α‐dependent SRC transcription which in turn controls CRC progression. Physiologically, our data indicate that IDH1 deacetylation represses CRC cell invasion and migration in vitro and in vivo, while the hyperacetylation of IDH1 on K224 is significantly correlated to distant metastasis and poor survival of colorectal cancer patients. In summary, our study uncovers a novel mechanism through which SIRT2‐dependent IDH1 deacetylation regulates cellular metabolism and inhibits liver metastasis of colorectal cancer.
Chemistry,Medicine,Biology
-
IDH1 K224 Acetylation Promotes Colorectal Cancer Via Mir-9-5p/nhe1 Axis-Mediated Regulation of Acidic Microenvironment.
Bo Wang,Long Zhao,Changjiang Yang,Yilin Lin,Shan Wang,Yingjiang Ye,Jianyuan Luo,Zhanlong Shen
DOI: https://doi.org/10.1016/j.isci.2023.107206
IF: 5.8
2023-01-01
iScience
Abstract:The acidic microenvironment is considered an important factor in colorectal cancer (CRC) that contributes to malignant transformation. However, the underlying mechanism remains unclear. In a previous study, we confirmed that IDH1 K224 deacetylation promotes enzymatic activity and the production of α-KG. Here, we further investigate the effect of IDH1 hyperacetylation on the CRC acidic microenvironment. We demonstrate that increased α-KG affects hydroxylation of Ago2 and mediates miR-9-5p targeting NHE1 protein. Knockdown of NHE1 dramatically attenuates CRC cell proliferation and migration by restricting transport of intracellular H+ out of cells. Furthermore, we show that miR-9-5p is the microRNA with the most significant difference in the alteration of IDH1 K224 acetylation and can downregulate NHE1 mRNA. Our data also indicate that hydroxylation stabilizes Ago2, which in turn promotes miR-9-5p activity. Taken together, our results reveal a novel mechanism through which IDH1 deacetylation regulates the cellular acidic microenvironment and inhibits CRC metastasis.
-
Lysine Acetylation Restricts Mutant IDH2 Activity to Optimize Transformation in AML Cells.
Dong Chen,Siyuan Xia,Rukang Zhang,Yuancheng Li,Christopher A. Famulare,Hao Fan,Rong Wu,Mei Wang,Allen C. Zhu,Shannon E. Elf,Rui Su,Lei Dong,Martha Arellano,William G. Blum,Hui Mao,Sagar Lonial,Wendy Stock,Olatoyosi Odenike,Michelle Le Beau,Titus J. Boggon,Chuan He,Jianjun Chen,Xue Gao,Ross L. Levine,Jing Chen
DOI: https://doi.org/10.1016/j.molcel.2021.06.027
IF: 16
2021-01-01
Molecular Cell
Abstract:Mutant isocitrate dehydrogenase (IDH) 1 and 2 play a pathogenic role in cancers, including acute myeloid leukemia (AML), by producing oncometabolite 2-hydroxyglutarate (2-HG). We recently reported that tyrosine phosphorylation activates IDH1 R132H mutant in AML cells. Here, we show that mutant IDH2 (mIDH2) R140Q commonly has K413 acetylation, which negatively regulates mIDH2 activity in human AML cells by attenuating dimerization and blocking binding of substrate (α-ketoglutarate) and cofactor (NADPH). Mechanistically, K413 acetylation of mitochondrial mIDH2 is achieved through a series of hierarchical phosphorylation events mediated by tyrosine kinase FLT3, which phosphorylates mIDH2 to recruit upstream mitochondrial acetyltransferase ACAT1 and simultaneously activates ACAT1 and inhibits upstream mitochondrial deacetylase SIRT3 through tyrosine phosphorylation. Moreover, we found that the intrinsic enzyme activity of mIDH2 is much higher than mIDH1, thus the inhibitory K413 acetylation optimizes leukemogenic ability of mIDH2 in AML cells by both producing sufficient 2-HG for transformation and avoiding cytotoxic accumulation of intracellular 2-HG.
-
TNFα-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity
Hao Yang,Xiaoping Zhao,Jianjun Liu,Mingming Jin,Xiyu Liu,Jun Yan,Xufeng Yao,Xinyi Mao,Nan Li,Beibei Liang,Wei Xie,Kunchi Zhang,Jian Zhao,Liu Liu,Gang Huang
DOI: https://doi.org/10.1038/s41388-022-02528-y
IF: 8.756
2022-11-11
Oncogene
Abstract:The heterogeneity and drug resistance of colorectal cancer (CRC) often lead to treatment failure. Isocitrate dehydrogenase 1 (IDH1), a rate-limiting enzyme in the tricarboxylic acid cycle, regulates the intracellular redox environment and mediates tumor cell resistance to chemotherapeutic drugs. The aim of this study was to elucidate the mechanism underlying the involvement of IDH1 acetylation in the development of CRC drug resistance under induction of TNFα. We found TNFα disrupted the interaction between SIRT1 and IDH1 and increased the level of acetylation at K115 of IDH1. Hyperacetylation of K115 was accompanied by protein ubiquitination, which increased its susceptibility to degradation compared to IDH1 K115R. TNFα-mediated hyperacetylation of K115 sensitized the CRC cells to 5FU and reduced the NADPH/NADP ratio to that of intracellular ROS. Furthermore, TNFα and 5FU inhibited CRC tumor growth in vivo, while the K115R-expressing tumor tissues developed 5FU resistance. In human CRC tissues, K115 acetylation was positively correlated with TNFα infiltration, and K115 hyperacetylation was associated with favorable prognosis compared to chemotherapy-induced deacetylation. Therefore, TNFα-induced hyperacetylation at the K115 site of IDH1 promotes antitumor redox homeostasis in CRC cells, and can be used as a marker to predict the response of CRC patients to chemotherapy.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
-
Global-scale profiling of differential expressed lysine acetylated proteins in colorectal cancer tumors and paired liver metastases
Zhanlong Shen,Bo Wang,Jianyuan Luo,Kewei Jiang,Hui Zhang,Harri Mustonen,Pauli Puolakkainen,Jun Zhu,Yingjiang Ye,Shan Wang
DOI: https://doi.org/10.1016/j.jprot.2016.05.002
2016-06-16
Abstract:Lysine acetylated modification was indicated to impact colorectal cancer (CRC)'s distant metastasis. However, the global acetylated proteins in CRC and the differential expressed acetylated proteins and acetylated sites between CRC primary and distant metastatic tumor remains unclear. Our aim was to construct a complete atlas of acetylome in CRC and paired liver metastases. Combining high affinity enrichment of acetylated peptides with high sensitive mass spectrometry, we identified 603 acetylation sites from 316 proteins, among which 462 acetylation sites corresponding to 243 proteins were quantified. We further classified them into groups according to cell component, molecular function and biological process and analyzed the metabolic pathways, domain structures and protein interaction networks. Finally, we evaluated the differentially expressed lysine acetylation sites and revealed that 31 acetylated sites of 22 proteins were downregulated in CRC liver metastases compared to that in primary CRC while 40 acetylated sites of 32 proteins were upregulated, of which HIST2H3AK19Ac and H2BLK121Ac were the acetylated histones most changed, while TPM2 K152Ac and ADH1B K331Ac were the acetylated non-histones most altered. These results provide an expanded understanding of acetylome in CRC and its distant metastasis, and might prove applicable in the molecular targeted therapy of metastatic CRC. Biological significance: This study described provides, for the first time, that full-scale profiling of lysine acetylated proteins were identified and quantified in colorectal cancer (CRC) and paired liver metastases. The novelty of the study is that we constructed a complete atlas of acetylome in CRC and paired liver metastases. Moreover, we analyzed these differentially expressed acetylated proteins in cell component, molecular function and biological process. In addition, metabolic pathways, domain structures and protein interaction networks of acetylated proteins were also investigated. Our approaches shows that of the differentially expressed proteins, HIST2H3AK19Ac and H2BLK121Ac were the acetylated histones most changed, while TPM2 K152Ac and ADH1B K331Ac were the acetylated non-histones most altered. Our findings provide an expanded understanding of acetylome in CRC and its distant metastasis, and might prove applicable in the molecular targeted therapy of metastatic CRC.
-
Profiles of Acetylation Regulation Genes Contribute to Malignant Progression and Have a Clinical Prognostic Impact on Liver Cancer
Wei Zhu,Xiaofen Zhang,Mengli Yu,Yu Zhang,Shaowei Li,Chaohui Yu
DOI: https://doi.org/10.1155/2022/1724301
2022-01-01
Disease Markers
Abstract:Background. Several studies have demonstrated that acetylation was involved in the process of liver cancer. This study aimed to establish an effective predictive prognostic model using acetylation regulation genes in liver cancer. Methods. Two datasets were downloaded from the Cancer Genome Atlas (TCGA) database and International Cancer Genome Consortium (ICGC) database. Differentially expressed acetylation regulation genes were identified in the TCGA-LIHC dataset, and then, Gene Ontology (GO) functional annotation analysis was used to investigate the molecular mechanism. After grouping the patients into clusters based on consensus clustering, we explored the correlation between clusters and clinical characteristics. A risk model was constructed by the least absolute shrinkage and selection operator (LASSO) regression analysis to calculate the risk score. Patients were divided into high-risk and low-risk groups according to the risk score using the acetylation regulation genes. Data downloaded from LIRI-JP were used for external validation. Univariate and multivariate Cox regressions were performed to identify independent risk factors. A prognostic nomogram was constructed according to the TCGA-LIHC dataset. The effect of HDAC11 expression on the proliferation and migration of liver cancer was detected by the CCK-8 method and cell scratch test, respectively. Results. Eleven of 29 acetylation regulation genes were identified as upregulated differentially expressed genes. Go enrichment analysis showed that they were involved in "protein and histone deacylation and deacetylation." Patients were categorized into two clusters according to the expression of 29 acetylation regulation genes. Compared with cluster 2, cluster 1 correlated with shorter overall survival (OS) and higher expression. Stage, T stage, grade, gender, age, and follow-up state were significantly different between two clusters. Pathways involved in DNA repair were significantly enriched in cluster 1. The risk score was calculated by HDAC1, HDAC2, HDAC4, HDAC11, HAT1, and SIRT6. Patients in the high-risk group had a worse prognosis in both datasets. Risk score was not only an independent prognostic marker but could also predict the clinicopathological features of liver cancer. A nomogram containing risk score, T stage, and M stage was built to predict overall survival. After transfection with HDAC11 overexpression plasmid, the proliferation ability of HepG2 cells increased, while the migration ability had no change. Conclusions. Our findings suggested that acetylation regulation genes contribute to malignant progression and have a clinical prognostic impact on liver cancer.
-
Supplementary Figures 1 - 13 from SIRT1 Limits the Function and Fate of Myeloid-Derived Suppressor Cells in Tumors by Orchestrating HIF-1<b>α</b>–Dependent Glycolysis
Guangwei Liu,Yujing Bi,Bo Shen,Hui Yang,Yan Zhang,Xiao Wang,Huanrong Liu,Yun Lu,Jiongbo Liao,Xi Chen,Yiwei Chu
DOI: https://doi.org/10.1158/0008-5472.22401441.v1
2023-01-01
Abstract:PDF file - 436K, Fig.S1. MDSC polarizing differentiation condition alters glycolytic activity. Fig.S2.MDSC SIRT1 expansions in spleen and tumor of SIRT1KO and WT-bearing tumor mice. Fig.S3.SIRT1 deficiency MDSCs showed normal cell death and proliferation. Fig.S4.SIRT1 is required for MDSC polarization. Fig.S5.Characterization of surface marker of bone marrow-derived MDSCs. Fig.S6.SIRT1 intrinsicly controls the function and differentiation of tumor MDSCs. Fig.S7.The potentiating killing activity of SIRT1-/- MDSCs is associated with the higher glycolytic activity. Fig.S8.CD115+ monocytic MDSC effects in tumor killing. Fig.S9.SIRT1 deficiency from MDSCs could not alter the activation of NF-κB signaling after LPS treatment. Fig.S10.SIRT1-dependent MDSC glycolytic activity changes are associated with mTOR-HIF1α pathway. Fig.S11.SIRT-HIF axis directs the function and fate of MDSC associated with glycolytic activity. Fig.S12.SIRT-HIF axis potentiates glycolytic activity and tumor killing ability. Fig.S13.SIRT1 masters MDSC function and fate in tumor through mTOR/HIF1α dependent glycolytic pathway.
-
The SIRT2-mediated Deacetylation of AKR1C1 is Required for Suppressing Its Pro-Metastasis Function in Non-Small Cell Lung Cancer.
Hong Zhu,Yan Hu,Chenming Zeng,Linlin Chang,Fujin Ge,Weihua Wang,Fangjie Yan,Qinxin Zhao,Ji Cao,Meidan Ying,Yongchuan Gu,Lin Zheng,Qiaojun He,Bo Yang
DOI: https://doi.org/10.7150/thno.39151
IF: 11.6
2020-01-01
Theranostics
Abstract:Aldo-keto reductase family 1 member C1 (AKR1C1) promotes malignancy of Non-Small Cell Lung Cancer (NSCLC) by activating Signal Transducer and Activator of Transcription 3 (STAT3) pathway. However, how the pro-metastatic functions of AKR1C1 are switched on/off remains unknown. Methods: Immunoprecipitation and LC-MS/MS analyses were performed to identify the acetylation on AKR1C1 protein, and the functional analyses (in vitro and in vivo) were performed to depict the contribution of acetylation to the pro-metastatic effects of AKR1C1. Results: Here we report that acetylated AKR1C1 on two lysine residues K185 & K201 is critical to its pro-metastatic role. The acetylation modification has no impact on the canonical enzymatic activity of AKR1C1, while it is required for the interaction between AKR1C1 to STAT3, which triggers the downstream transduction events, ultimately mobilizing cells. Importantly, the deacetylase Sirtuin 2 (SIRT2) is capable of deacetylating AKR1C1, inhibiting the transactivation of STAT3 target genes, thus suppressing the migration of cells. Conclusion: Acetylation on Lysines 185 and 201 of AKR1C1 dictates its pro-metastatic potential both in vitro and in vivo, and the reverting of acetylation by Sirtuin 2 provides potential therapeutic targets for treatment against metastatic NSCLC patients with high AKR1C1 expression.
-
SIRT5‐mediated Deacetylation of LDHB Promotes Autophagy and Tumorigenesis in Colorectal Cancer
Liang Shi,Hui Yan,Shuxian An,Mengqin Shen,Wenzhi Jia,Ruixue Zhang,Li Zhao,Gang Huang,Jianjun Liu
DOI: https://doi.org/10.1002/1878-0261.12408
2018-01-01
Molecular Oncology
Abstract:Lactate dehydrogenase B (LDHB) is a glycolytic enzyme that catalyses the conversion of lactate and NAD+ to pyruvate, NADH and H+. Protons (H+) generated by LDHB promote lysosomal acidification and autophagy in cancer, but how this role is regulated has not been defined. In this study, we identified an important post‐translational mechanism by which LDHB is regulated during autophagy in cancer cells. Mass spectrometry revealed that protein sirtuin 5 (SIRT5) is a binding partner of LDHB that deacetylated LDHB at lysine‐329, thereby promoting its enzymatic activity. Deacetylated LDHB increased autophagy and accelerated the growth of colorectal cancer (CRC) cells. Notably, SIRT5 knockout or inhibition by GW5074 increased LDHB acetylation at K329 and inhibited LDHB activity, which downregulated autophagy and CRC cell growth in vitro and in vivo. Clinically, the LDHB‐Ac‐K329 staining score in CRC tissues was lower than that in corresponding peritumour tissues. Low LDHB‐Ac‐K329 status was associated with malignant progression of human CRC and served as a potential prognostic indicator for patients with CRC. Altogether, we conclude that SIRT5‐induced deacetylation of LDHB triggers hyperactivation of autophagy, a key event in tumorigenesis. Thus, the SIRT5/LDHB pathway may represent a novel target for treating CRC.
-
Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway
Shixiong Liu,Yun Zhou,Yarong Chen,Yuqin Qiao,Lumucao Bai,Shenhua Zhang,Dongfang Men,Haibu Zhang,Fen Pan,Yongshen Gao,Jijing Wang,Yuping Wang
DOI: https://doi.org/10.1016/j.intimp.2024.112828
2024-10-25
Abstract:Changes in isocitrate dehydrogenases (IDH) lead to the production of the cancer-causing metabolite 2-hydroxyglutarate, making them a cause of cancer. However, the specific role of IDH in the progression of colon cancer is still not well understood. Our current study provides evidence that IDH2 is significantly increased in colorectal cancer (CRC) cells and actively promotes cell growth in vitro and the development of tumors in vivo. Inhibiting the activity of IDH2, either through genetic silencing or pharmacological inhibition, results in a significant increase in α-ketoglutarate (α-KG), indicating a decrease in the reductive citric acid cycle. The excessive accumulation of α-KG caused by the inactivation of IDH2 obstructs the generation of ATP in mitochondria and promotes the downregulation of HIF-1A, eventually inhibiting glycolysis. This dual metabolic impact results in a reduction in ATP levels and the suppression of tumor growth. Our study reveals a metabolic trait of colorectal cancer cells, which involves the active utilization of glutamine through reductive citric acid cycle metabolism. The data suggests that IDH2 plays a crucial role in this metabolic process and has the potential to be a valuable target for the advancement of treatments for colorectal cancer.
-
SIRT3 Protein Deacetylates Isocitrate Dehydrogenase 2 (IDH2) and Regulates Mitochondrial Redox Status
Wei Yu,Kristin E. Dittenhafer-Reed,John M. Denu
DOI: https://doi.org/10.1074/jbc.m112.355206
2012-01-01
Abstract:Mitochondria play a central role in oxidative energy metabolism and age-related diseases such as cancer. Accumulation of spurious oxidative damage can cause cellular dysfunction. Antioxidant pathways that rely on NADPH are needed for the reduction of glutathione and maintenance of proper redox status. The mitochondrial matrix protein isocitrate dehydrogenase 2 (IDH2) is a major source of NADPH. Previously, we demonstrated that the NAD(+)-dependent deacetylase SIRT3 was essential for the prevention of age-related hearing loss in mice fed a calorically restricted diet. Here we provide direct biochemical and biological evidence establishing an exquisite regulatory relationship between IDH2 and SIRT3 under acute and chronic caloric restriction. The regulated site of acetylation was mapped to Lys-413, an evolutionarily invariant residue. Site-specific, genetic incorporation of N-e-acetyllysine into position 413 of IDH2 revealed that acetylated IDH2 displays a dramatic 44-fold loss in activity. Deacetylation by SIRT3 fully restored maximum IDH2 activity. The ability of SIRT3 to protect cells from oxidative stress was dependent on IDH2, and the deacetylated mimic, IDH2(K413R) variant was able to protect Sirt3(-/-) mouse embryonic fibroblasts from oxidative stress through increased reduced glutathione levels. Together these results uncover a previously unknown mechanism by which SIRT3 regulates IDH2 under dietary restriction. Recent findings demonstrate that IDH2 activities are a major factor in cancer, and as such, these results implicate SIRT3 as a potential regulator of IDH2-dependent functions in cancer cell metabolism.
-
Deacetylation of Serine Hydroxymethyl-Transferase 2 by SIRT3 Promotes Colorectal Carcinogenesis
Zhen Wei,Jinglue Song,Guanghui Wang,Ximao Cui,Jun Zheng,Yunlan Tang,Xinyuan Chen,Jixi Li,Long Cui,Chenying Liu,Wei Yu
DOI: https://doi.org/10.1038/s41467-018-06812-y
IF: 16.6
2018-01-01
Nature Communications
Abstract:The conversion of serine and glycine that is accomplished by serine hydroxymethyltransferase 2 (SHMT2) in mitochondria is significantly upregulated in various cancers to support cancer cell proliferation. In this study, we observed that SHMT2 is acetylated at K95 in colorectal cancer (CRC) cells. SIRT3, the major deacetylase in mitochondria, is responsible for SHMT2 deacetylation. SHMT2-K95-Ac disrupts its functional tetramer structure and inhibits its enzymatic activity. SHMT2-K95-Ac also promotes its degradation via the K63-ubiquitin–lysosome pathway in a glucose-dependent manner. TRIM21 acts as an E3 ubiquitin ligase for SHMT2. SHMT2-K95-Ac decreases CRC cell proliferation and tumor growth in vivo through attenuation of serine consumption and reduction in NADPH levels. Finally, SHMT2-K95-Ac is significantly decreased in human CRC samples and is inversely associated with increased SIRT3 expression, which is correlated with poorer postoperative overall survival. Our study reveals the unknown mechanism of SHMT2 regulation by acetylation which is involved in colorectal carcinogenesis.
-
IDO in Colorectal Tumorigenesis: Involvement of Immune Tolerance and Significance in Prevention and Therapy
Shunan Tang,Jingya Wang,Siwang Yu
DOI: https://doi.org/10.1016/j.jcmgh.2021.06.021
2021-01-01
Abstract:Colorectal cancer (CRC) ranks third in incidence and second in mortality worldwide,1Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin. 2021; 71: 209-249Crossref PubMed Scopus (9275) Google Scholar and the incidence rates have been increasing in less developed regions and in younger individuals in many developed countries.2Siegel R.L. Miller K.D. Goding Sauer A. Fedwa S.A. Butterfly L.F. Anderson J.C. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164Crossref PubMed Scopus (1449) Google Scholar Despite the significant improvements in primary prevention, screening, and to a lesser extent, treatment,2Siegel R.L. Miller K.D. Goding Sauer A. Fedwa S.A. Butterfly L.F. Anderson J.C. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164Crossref PubMed Scopus (1449) Google Scholar the prognosis of patients with metastatic colorectal cancer (mCRC) remains poor.3Ganesh K. Stadler Z.K. Cercek A. Mendelsohn R.B. Shia J. Segal N.H. Diaz Jr., L.A. Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019; 16: 361-375Crossref PubMed Scopus (406) Google Scholar Recently, immune checkpoint inhibitors (ICIs) demonstrated exciting efficacy in CRC characterized by mismatch repair (MMR)–deficient or high levels of microsatellite instability (MSI) in multiple clinical trials, and pembrolizumab, nivolumab, and the combination of nivolumab and ipilimumab have been approved by the U.S. Food and Drug Administration for treatment of MMR-deficient/high MSI CRCs.3Ganesh K. Stadler Z.K. Cercek A. Mendelsohn R.B. Shia J. Segal N.H. Diaz Jr., L.A. Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019; 16: 361-375Crossref PubMed Scopus (406) Google Scholar However, the majority of CRC (85%) and mCRC (95%) cases are MMR-proficient or MSI low and are essentially nonresponsive to ICIs.3Ganesh K. Stadler Z.K. Cercek A. Mendelsohn R.B. Shia J. Segal N.H. Diaz Jr., L.A. Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol. 2019; 16: 361-375Crossref PubMed Scopus (406) Google Scholar Other potential immunotherapies and combinations, including ICIs other than inhibitors of PD-1/PD-L1 or CTLA-4, are under active pursuing. IDO is one of the well-recognized immune suppressive molecules. Both IDO and TDO catalyze the rate-limiting cleavage of essential amino acid tryptophan (Trp) into kynurenine (Kyn) pathway, resulting in depletion of Trp and production of immunoregulatory molecules including Kyn. While TDO exists mainly in liver and brain, IDO, specifically IDO1, is expressed in certain endothelial and epithelial cells in response to certain pathological conditions such as inflammation and cancer.4Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.Eur J Pharmacol. 2021; 896: 173921Crossref PubMed Scopus (10) Google Scholar High IDO expression in CRC is associated with immune tolerance, metastasis, and poor prognosis, and increased serum Kyn-to-Trp ratio could serve as a screening marker of CRC.4Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.Eur J Pharmacol. 2021; 896: 173921Crossref PubMed Scopus (10) Google Scholar Kyn is an agonist of aromatic hydrocarbon receptor (AhR), which induces differentiation of regulatory T (Treg) cells and the expression of PD-1 in CD8+ T cells,4Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.Eur J Pharmacol. 2021; 896: 173921Crossref PubMed Scopus (10) Google Scholar and intestinal epithelial loss of AhR enhanced cecum and colon tumorigenesis.5Han H. Davidson L.A. Hensel M. Yoon G. Landrock K. Allred C. Jayaraman A. Ivanov I. Safe S.H. Chapkin R.S. Loss of aryl hydrocarbon receptor promotes colon tumorigenesis in Apc(S580/+); Kras(G12D/+) mice.Mol Cancer Res. 2021; 19: 771-783Crossref PubMed Scopus (4) Google Scholar Mechanistically, IDO and its Kyn pathway metabolites have been reported to activate β-catenin and PI3K-Akt signaling pathways to promote cancer cell proliferation and inhibit apoptosis and thus facilitate colon tumorigenesis.6Bishnupuri K.S. Alvarado D.M. Khouri A.N. Shabsovich M. Chen B. Dieckgraefe B.K. Ciorbia M.A. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis.Cancer Res. 2019; 79: 1138-1150Crossref PubMed Scopus (62) Google Scholar,7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar However, the involvement of IDO in immune tolerance, which has been well characterized in other cancers and is more relevant to immunotherapy efficacy, has not been determined in CRC, and the exact mechanisms by which IDO regulates the fate of immune cells in colorectal tumor microenvironment remain unknown. In this issue of Cellular and Molecular Gastroenterology and Hepatology, Zhang et al8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar carefully examined the impact of activated IDO in colon cancer cells on T cells and mice spleen lymphocytes using conditioned medium from IDO-activated colon cancer cells, then validated their findings using azoxymethane (AOM)/dextran sodium sulfate (DSS)–induced colitis-associated cancer (CAC) model in IDO–/–, Rag1–/–, and wild-type mice.8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar The conditioned medium inhibited proliferation of activated T cells (Jurkat cells) by cell cycle arrest, and promoted transdifferentiation of mice spleen lymphocytes into FoxP3+ Treg cells instead of CD8+ T cells, in a Trp-independent, AhR-dependent, and Kyn-like manner. These results not only confirmed the immune-suppressive effects of IDO activation in CRC, but also provided new mechanistic interpretation of the previously documented IDO-mediated increase of Treg cells in CRC mice models.9Takamatsu M. Hirata A. Ohtaki H. Hoshi M. Ando T. Ito H. Hatano Y. Tomita H. Kuno T. Saito K. Seishima M. Hara A. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.Cancer Sci. 2015; 106: 1008-1015Crossref PubMed Scopus (37) Google Scholar Previous studies reported that both genetic knockout and pharmacological inhibition of IDO attenuated AOM/DSS-induced mice colon tumorigenesis, while the involvement of adaptive immune response was excluded.6Bishnupuri K.S. Alvarado D.M. Khouri A.N. Shabsovich M. Chen B. Dieckgraefe B.K. Ciorbia M.A. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis.Cancer Res. 2019; 79: 1138-1150Crossref PubMed Scopus (62) Google Scholar,7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar Zhang et al8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar demonstrated similar phenotypic results in the present article and their previous publication.10Liu X. Zhou W. Zhang X. Ding Y. Du Q. Hu R. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.Int J Cancer. 2018; 143: 1516-1529Crossref PubMed Scopus (23) Google Scholar Interestingly, decreased Treg cells and increased CD8+ T cells were detected in tumors of IDO–/– CAC mice, while Kyn treatment significantly counteracted the effects of IDO deficiency, suggesting an important role of IDO-Kyn-AhR-FoxP3–mediated immune-suppressive environment in colon tumorigenesis. It is noteworthy that the role of AhR in colon tumorigenesis has been controversial, and it has also been recognized as a tumor suppressor.5Han H. Davidson L.A. Hensel M. Yoon G. Landrock K. Allred C. Jayaraman A. Ivanov I. Safe S.H. Chapkin R.S. Loss of aryl hydrocarbon receptor promotes colon tumorigenesis in Apc(S580/+); Kras(G12D/+) mice.Mol Cancer Res. 2021; 19: 771-783Crossref PubMed Scopus (4) Google Scholar,11Campesato L.F. Budhu S. Tchaicha J. Went C.-H. Gigoux M. Cohen I.J. Redmond D. Mangarin L. Pourpe S. Liu C. Zappasodi R. Zamarin D. Cavanaugh J. Castro A.C. Manfredi M.G. McGovern K. Merghoub T. Wolchok J.D. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.Nat Commun. 2020; 11: 4011Crossref PubMed Scopus (60) Google Scholar Such controversary might result from the complexity and plasticity of AhR signaling,12Leclerc D. Staats Pires A.C. Guillemin G.J. Gilot D. Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies.Curr Opin Immunol. 2021; 70: 15-26Crossref PubMed Scopus (13) Google Scholar and thus AhR may not be a good target candidate of immunotherapies. On the other hand, Rag1–/– mice without mature T and B cells were more susceptible to AOM/DSS-induced CAC, which further supports the importance of T cells in colon carcinogenesis. Surprisingly, IDO deficiency in a Rag1–/– background (IDO–/–::Rag–/– mice) also inhibited AOM/DSS-induced CAC,7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar suggesting that further investigations are guaranteed. Among the known immune checkpoint molecules, IDO is the only one that can be targeted by small molecules. Therefore, IDO inhibitors are of special interest to medicinal chemists and pharmaceutical industry. IDO inhibitors or in combination with anti-PD-1/PD-L1 therapies have been extensively investigated in various cancers, and very promising results have been obtained in preclinical and early phase clinical investigations. Unfortunately, the enthusiasm has been greatly dampened by lack of efficacy in recent clinical trials.13Companies Scaling Back IDO1 Inhibitor Trials.Cancer Discov. 2018; 8: OF5Crossref Scopus (11) Google Scholar However, as suggested by Zhang et al8Zhang X. Liu X. Zhou W. Du Q. Yang M. Ding Y. Hu R. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance.Cell Mol Gastroenterol Hepatol. 2021; 12: 1179-1199Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar,10Liu X. Zhou W. Zhang X. Ding Y. Du Q. Hu R. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells.Int J Cancer. 2018; 143: 1516-1529Crossref PubMed Scopus (23) Google Scholar and others,14Fletcher R. Wang Y.J. Schoen R.E. Finn O.J. Yu J. Zhang L. Colorectal cancer prevention: Immune modulation taking the stage.Biochim Biophys Acta Rev Cancer. 2018; 1869: 138-148Crossref PubMed Scopus (41) Google Scholar IDO inhibitors may find a better avenue in prevention of CRC. Indeed, the inducible expression of IDO by inflammatory stimuli is especially interesting for colorectal carcinogenesis, as inflammatory bowel diseases are well recognized as a risk factor of CRC.2Siegel R.L. Miller K.D. Goding Sauer A. Fedwa S.A. Butterfly L.F. Anderson J.C. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164Crossref PubMed Scopus (1449) Google Scholar Chemoprevention of CRC by anti-inflammatory drugs such as celecoxib and aspirin has been successful. Although inhibition of IDO may augment colitis,15Gurtner G.J. Newberry R.D. Schloemann S.R. McDonald K.G. Stenson W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.Gastroenterology. 2003; 125: 1762-1773Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar Thaker et al7Thaker A.I. Rao M.S. Bishnupuri K.S. Kerr T.A. Foster L. Marinshaw J.M. Newberry R.D. Stenson W.F. Ciorba M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013; 145: 416-425.e1-4Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar proved that such an effect was dependent on the severity of colitis. IDO inhibitors, at the crossroad of chemoprevention and immunoprevention, definitely deserve further investigation as a preventive agent of CRC or therapy of precancerous colorectal lesions. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune ToleranceCellular and Molecular Gastroenterology and HepatologyVol. 12Issue 4PreviewChronic inflammation in colon section is associated with an increased risk of colorectal cancer (CRC). Proinflammatory cytokines were produced in a tumor microenvironment and correlated with poor clinical outcome. Tumor-infiltrating T cells were reported to be greatly involved in the development of colon cancer. In this study, we demonstrated that kynurenine (Kyn), a metabolite catalyzed by indoleamine 2,3-dioxygenase (IDO), was required for IDO-mediated T cell function, and adaptive immunity indeed played a critical role in CRC. Full-Text PDF Open Access
-
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
Katsuhiko Nosho,Kaori Shima,Natsumi Irahara,Shoko Kure,Ron Firestein,Yoshifumi Baba,Saori Toyoda,Li Chen,Aditi Hazra,Edward L Giovannucci,Charles S Fuchs,Shuji Ogino
DOI: https://doi.org/10.1038/modpathol.2009.49
IF: 8.209
2009-05-08
Modern Pathology
Abstract:The class III histone deacetylase SIRT1 (sir2) is important in epigenetic gene silencing. Inhibition of SIRT1 reactivates silenced genes, suggesting a possible therapeutic approach of targeted reversal of aberrantly silenced genes. In addition, SIRT1 may be involved in the well-known link between obesity, cellular energy balance and cancer. However, a comprehensive study of SIRT1 using human cancer tissue with clinical outcome data is currently lacking, and its prognostic significance is uncertain. Using the database of 485 colorectal cancers in two independent prospective cohort studies, we detected SIRT1 overexpression in 180 (37%) tumors by immunohistochemistry. We examined its relationship to the CpG island methylator phenotype (CIMP), related molecular events, clinical features including body mass index, and patient survival. We quantified DNA methylation in eight CIMP-specific promoters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) and eight other CpG islands (CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14, and WRN) by MethyLight. SIRT1 overexpression was associated with CIMP-high (≥6 of 8 methylated CIMP-specific promoters, P=0.002) and microsatellite instability (MSI)-high phenotype (P<0.0001). In both univariate and multivariate analyses, SIRT1 overexpression was significantly associated with the CIMP-high MSI-high phenotype (multivariate odds ratio, 3.20; 95% confidence interval, 1.35–7.59; P=0.008). In addition, mucinous component (P=0.01), high tumor grade (P=0.02), and fatty acid synthase overexpression (P=0.04) were significantly associated with SIRT positivity in multivariate analysis. SIRT1 was not significantly related with age, sex, tumor location, stage, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, β-catenin, COX-2, or patient prognosis. In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.
pathology
-
Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming
Marina Koutsioumpa,Maria Hatziapostolou,Christos Polytarchou,Ezequiel J Tolosa,Luciana L Almada,Swapna Mahurkar-Joshi,Jennifer Williams,Ana Belen Tirado-Rodriguez,Sara Huerta-Yepez,Dimitrios Karavias,Helen Kourea,George A Poultsides,Kevin Struhl,David W Dawson,Timothy R Donahue,Martín E Fernández-Zapico,Dimitrios Iliopoulos
DOI: https://doi.org/10.1136/gutjnl-2017-315690
IF: 24.5
2018-10-18
Gut
Abstract:Objective Despite advances in the identification of epigenetic alterations in pancreatic cancer, their biological roles in the pathobiology of this dismal neoplasm remain elusive. Here, we aimed to characterise the functional significance of histone lysine methyltransferases (KMTs) and demethylases (KDMs) in pancreatic tumourigenesis. Design DNA methylation sequencing and gene expression microarrays were employed to investigate CpG methylation and expression patterns of KMTs and KDMs in pancreatic cancer tissues versus normal tissues. Gene expression was assessed in five cohorts of patients by reverse transcription quantitative-PCR. Molecular analysis and functional assays were conducted in genetically modified cell lines. Cellular metabolic rates were measured using an XF24-3 Analyzer, while quantitative evaluation of lipids was performed by liquid chromatography-mass spectrometry (LC-MS) analysis. Subcutaneous xenograft mouse models were used to evaluate pancreatic tumour growth in vivo. Results We define a new antitumorous function of the histone lysine (K)-specific methyltransferase 2D (KMT2D) in pancreatic cancer. KMT2D is transcriptionally repressed in human pancreatic tumours through DNA methylation. Clinically, lower levels of this methyltransferase associate with poor prognosis and significant weight alterations. RNAi-based genetic inactivation of KMT2D promotes tumour growth and results in loss of H3K4me3 mark. In addition, KMT2D inhibition increases aerobic glycolysis and alters the lipidomic profiles of pancreatic cancer cells. Further analysis of this phenomenon identified the glucose transporter SLC2A3 as a mediator of KMT2D-induced changes in cellular, metabolic and proliferative rates. Conclusion Together our findings define a new tumour suppressor function of KMT2D through the regulation of glucose/fatty acid metabolism in pancreatic cancer.
gastroenterology & hepatology
-
Abstract 1058: Mutations in Isocitrate Dehydrogenase 1 and 2 Are Associated with DNA Hypermethylation in Intrahepatic Cholangiocarcinomas
Pu Wang,Qiong-Zhu Dong,Chong Zhang,Pei -Fen Kuan,Yufeng Liu,William R. Jeck,Jesper B. Andersen,James Todd Auman,Janelle M. Hoskins,Jin Woo Kim,Kristian Cibulskis,Gad Getz,Heike V. Hunt,Snorri S. Thorgeirsson,Lewis R. Roberts,Dan Ye,Kun-Liang Guan,Yue Xiong,Lun-Xiu Qin,Derek Y. Chiang
DOI: https://doi.org/10.1158/1538-7445.am2012-1058
IF: 11.2
2012-01-01
Cancer Research
Abstract:Abstract Cholangiocarcinomas are rare but aggressive cancers, with an increasing incidence and a dismal 5-year survival rate of less than 5%. Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been reported in ∼70% of gliomas, ∼20% of myeloid leukemias, ∼56% of chondrosarcomas, and ∼10% of melanomas. We discovered IDH1 and IDH2 mutations in 29 of 305 (9%) intrahepatic cholangiocarcinomas. Tumors with mutations in IDH1 or IDH2 had lower 5-hydroxymethylcytosine and higher 5-methylcytosine levels, as well as increased dimethylation of histone H3K79. Mutations in IDH1 or IDH2 were independently associated with longer time to recurrence of cholangiocarcinoma in multivariate analysis (p = 0.046). We identified 2,267 genes that were significantly hypermethylated in tumors with mutations in IDH1 or IDH2. Hypermethylated CpG sites were significantly enriched in CpG shores and in the 1500 bp upstream of annotated transcription start sites, suggesting a global regulation of transcriptional potential. Gene expression profiling of 7 IDH1/2-mutant and 20 IDH1/2-wildtype tumors revealed increased expression of citric acid cycle and oxidative phosphorylation enzymes, as well as decreased expression of cytoskeleton organization genes. Integrated analyses of DNA methylation and gene expression identified interleukin-6 and several of its downstream targets as candidates for silencing by DNA methylation. Conclusions: Cholangiocarcinomas with mutations in IDH1 or IDH2 represent a molecular subclass with distinct signaling pathway alterations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1058. doi:1538-7445.AM2012-1058
-
Abstract 1718: The lysine demethylase KDM2A regulates tumor cell clustering to potentiate metastasis
Carolyn Kravitz,Kiran D. Patel,Wesley L. Cai,Anna Arnal-Estapé,Dejian Zhao,Emily Wingrove,Laura Stevens,Thomas F. Westbrook,Qin Yan,Don X. Nguyen
DOI: https://doi.org/10.1158/1538-7445.am2024-1718
IF: 11.2
2024-03-23
Cancer Research
Abstract:Approximately 70% of patients diagnosed with non-small cell lung cancer (NSCLC) are not eligible for curative resection, often due to disseminated disease at diagnosis. Thus, the advent of novel therapeutics, especially those efficacious for metastatic disease, is of primary importance. Metastasis correlates with epigenetic alterations that drive tumor plasticity and adaptive heterogeneity in response to the multiple microenvironments metastatic cells see, yet the molecular mechanisms underlying these epigenetic alterations remain poorly understood. We performed a functional genomic screen and identified the lysine 36 on histone H3 (H3K36) demethylase KDM2A as a mediator of in vivo and in vitro metastatic competence in multiple models of NSCLC. KDM2A depletion in highly metastatic NSCLC cell lines reduces their capacity to form multi-tumor cell clusters. In vivo, KDM2A depletion does not impact lung orthotopic tumor cell growth or the total number of circulating tumor cells (CTCs) but does reduce their ability to colonize distant metastatic sites. This is consistent with the fact that human CTCs found in clusters are more metastatic than CTCs which disseminate as single-cells. Because the molecular and biological consequences of H3K36 regulation are context dependent, we performed for the first time an integrated transcriptomic-epigenomic analysis of target gene regulation, KDM2A genomic binding, H3K36 methylation, and H3K27 acetylation, in metastatic cell clusters. KDM2A enhances the expression of cell adhesion and anti-oxidant genes, while suppressing inflammatory gene responses, and this regulation preferentially occurs in tumor cell clusters. Transcriptomic analysis of CTCs from patients confirms that KDM2A regulated transcriptional responses correlate with metastatic relapse across multiple cancer types. Moreover, KDM2A may function both as a transcriptional activator and repressor in metastatic clusters. As KDM2A encodes for several domains which can independently regulate E3-ubiqutin ligation, H3K36me2 demethylation, and DNA methylation, we have also performed a structure function analysis of K2MDA in the context of metastatic phenotypes. Thus, the distinct biochemical functions of KDM2A in relation to its regulation of CTC gene transcription and histone modification will also be presented. In conclusion, we have identified KDM2A as a novel regulator of NSCLC metastatic spread. The ability to inhibit KDM2A with small molecule inhibitors may be translated into effective therapeutic interventions for NSCLC patients with metastasis disease. Citation Format: Carolyn Kravitz, Kiran D. Patel, Wesley L. Cai, Anna Arnal-Estapé, Dejian Zhao, Emily Wingrove, Laura Stevens, Thomas F. Westbrook, Qin Yan, Don X. Nguyen. The lysine demethylase KDM2A regulates tumor cell clustering to potentiate metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1718.
oncology
-
Acetylation of PGK1 at lysine 323 promotes glycolysis, cell proliferation, and metastasis in luminal A breast cancer cells
Xiuli Gao,Ting Pan,Yu Gao,Wenbin Zhu,Likun Liu,Wenbo Duan,Cuicui Han,Bo Feng,Wenjing Yan,Qiuhang Song,Yunlong Liu,Liling Yue
DOI: https://doi.org/10.1186/s12885-024-12792-8
IF: 4.638
2024-08-27
BMC Cancer
Abstract:Background: In prior research employing iTRAQ (Isobaric Tags for Relative and Absolute Quantitation) technology, we identified a range of proteins in breast cancer tissues exhibiting high levels of acetylation. Despite this advancement, the specific functions and implications of these acetylated proteins in the context of cancer biology have yet to be elucidated. This study aims to systematically investigate the functional roles of these acetylated proteins with the objective of identifying potential therapeutic targets within breast cancer pathophysiology. Methods: Acetylated targets were identified through bioinformatics, with their expression and acetylation subsequently confirmed. Proteomic analysis and validation studies identified potential acetyltransferases and deacetylases. We evaluated metabolic functions via assays for catalytic activity, glucose consumption, ATP levels, and lactate production. Cell proliferation and metastasis were assessed through viability, cycle analysis, clonogenic assays, PCNA uptake, wound healing, Transwell assays, and MMP/EMT marker detection. Results: Acetylated proteins in breast cancer were primarily involved in metabolism, significantly impacting glycolysis and the tricarboxylic acid cycle. Notably, PGK1 showed the highest acetylation at lysine 323 and exhibited increased expression and acetylation across breast cancer tissues, particularly in T47D and MCF-7 cells. Notably, 18 varieties acetyltransferases or deacetylases were identified in T47D cells, among which p300 and Sirtuin3 were validated for their interaction with PGK1. Acetylation at 323 K enhanced PGK1's metabolic role by boosting its activity, glucose uptake, ATP production, and lactate output. This modification also promoted cell proliferation, as evidenced by increased viability, S phase ratio, clonality, and PCNA levels. Furthermore, PGK1-323 K acetylation facilitated metastasis, improving wound healing, cell invasion, and upregulating MMP2, MMP9, N-cadherin, and Vimentin while downregulating E-cadherin. Conclusion: PGK1-323 K acetylation was significantly elevated in T47D and MCF-7 luminal A breast cancer cells and this acetylation could be regulated by p300 and Sirtuin3. PGK1-323 K acetylation promoted cell glycolysis, proliferation, and metastasis, highlighting novel epigenetic targets for breast cancer therapy.
-
SIRT1 deacetylates WEE1 and sensitizes cancer cells to WEE1 inhibition
Xiaomei Zhu,Qunshu Su,Haiyuan Xie,Lizhi Song,Fan Yang,Dandan Zhang,Binghong Wang,Shixian Lin,Jun Huang,Mengjie Wu,Ting Liu
DOI: https://doi.org/10.1038/s41589-022-01240-y
IF: 14.8
2023-01-13
Nature Chemical Biology
Abstract:The cell-cycle checkpoint kinase WEE1 is emerging as a therapeutic target for cancer treatment. However, how its catalytic activity is regulated remains poorly understood, and reliable biomarkers for predicting response to WEE1 inhibitor remain to be identified. Here we identify an evolutionarily conserved segment surrounding its Lys177 residue that inhibits WEE1 activity through an intermolecular interaction with the catalytic kinase domain. Upon DNA damage, CHK1-dependent phosphorylation of WEE1 at Ser642 primes GCN5-mediated acetylation at Lys177, resulting in dissociation of the inhibitory segment from the kinase domain and subsequent activation of WEE1 and cell-cycle checkpoints. Conversely, SIRT1 associates with and deacetylates WEE1, which maintains it in an inactive state. Consequently, SIRT1 deficiency induces WEE1 hyperacetylation and activation, rendering cancer cells resistant to WEE1 inhibition. These results suggest that SIRT1 expression level and abundance of WEE1 Lys177 acetylation in tumor cells can serve as useful biomarkers for predicting WEE1 inhibitor sensitivity or resistance.
biochemistry & molecular biology
-
HDAC8-dependent Deacetylation of PKM2 Directs Nuclear Localization and Glycolysis to Promote Proliferation in Hepatocellular Carcinoma.
Ruixue Zhang,Mengqin Shen,Chunhua Wu,Yumei Chen,Jiani Lu,Jiajin Li,Li Zhao,Huannan Meng,Xiang Zhou,Gang Huang,Xiaoping Zhao,Jianjun Liu
DOI: https://doi.org/10.1038/s41419-020-03212-3
2020-01-01
Cell Death and Disease
Abstract:Pyruvate kinase M2 (PKM2) is not only a key rate-limiting enzyme that guides glycolysis, but also acts as a non-metabolic protein in regulating gene transcription. In recent years, a series of studies have confirmed that post-translational modification has become an important mechanism for regulating the function of PKM2, which in turn affects tumorigenesis. In this study, we found that K62 residues were deacetylated, which is related to the prognosis of HCC. Further studies indicate that HDAC8 binds and deacetylates the K62 residue of PKM2. Mechanistically, K62 deacetylation facilitate PKM2 transport into the nucleus and bind β-catenin, thereby promoting CCND1 gene transcription and cell cycle progression. In addition, the deacetylation of K62 affects the enzyme activity of PKM2 and the flux of glucose metabolism. Therefore, these results suggest that HDAC8 / PKM2 signaling may become a new target for the treatment of HCC.